Beijing Scitech-mq Pharmaceuticals Limited

Boe Technology Group Co., Ltd.

Hefei Boe Optoelectronics Technology Co., Ltd.

Hailong Yang

Qiang Zhang

Hongbo Zhang

Leifu Yang

Shannan Yu

Nanqiao Zheng

Likai Zhou

Shouye Feng

Zhanqiang Xu

Zhongxiang Wang

Chenming Hu

Yansheng Liu

Hanqi Chu

Xingfu Li

Xun Gu

Yueming Sun

Wenjuan Mei

Wenquan Chu

Shibao Wang

A substrate includes a base, a pixel defining layer, a plurality of electrode pairs, and a plurality of light-emitting devices. The pixel defining layer is disposed on the base, and includes a plurality of through holes. At least one electrode pair includes a first electrode and a second electrode that are disposed at least on a hole wall of one of the through holes and at least partially opposite to each other, and the first electrode and the second electrode are insulated from each other. One of the plurality of light-emitting devices includes a liquid functional layer disposed in the through hole. The liquid functional layer is in direct contact with the first electrode and the second electrode. The liquid functional layer includes a liquid light-emitting layer configured to emit light.

Substrate and display panel

Provided are an oxazino-quinazoline and oxazino-quinoline type compound, a preparation method, and uses thereof. More particularly provided is a compound shown in formula (I), an isomer, a hydrate, a solvate, a pharmaceutically acceptable salt, a prodrug thereof, a preparation method, and uses thereof in preparing a drug acting as a kinase inhibitor. 

Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof

The present invention relates to an urea-substituted aromatic ring-linked dioxinoquinoline compound of formula (I), or a pharmaceutically acceptable salt or a hydrate thereof. The invention also provides a preparation method of the compound of formula (I) and a pharmaceutically acceptable salt thereof, as well as uses thereof as a drug, wherein the drug acting as a tyrosine kinase (i.e. VEGFR-2, C-RAF, B-RAF, and RET) inhibitor is used for treating disorders related to tyrosine kinase. 

Urea-substituted aromatic ring-linked dioxinoquinoline compounds, preparation method and uses thereof

The present invention relates to a dioxinoquinoline compound of formula (I) or a pharmaceutically acceptable salt thereof. The invention also provides a preparation method of the compound of formula (I) and a pharmaceutically acceptable salt thereof, as well as uses thereof as a drug, wherein the drug acting as a tyrosine kinase (i.e. VEGFR-2 and c-MET) inhibitor is used for treating disorders related to tyrosine kinase. 

Dioxinoquinoline compounds, preparation method and uses thereof

The present invention relates to a urea-substituted aromatic ring-linked dioxinoquinazoline and a urea-substituted aromatic ring-linked dioxinoquinoline of Formula (I), or a pharmaceutically acceptable salt thereof or a hydrate thereof. Also provided are the preparation of the compound as shown in Formula (I) and the pharmaceutically acceptable salt thereof and the use thereof as a drug. The drug is used as an inhibitor of tyrosine kinases (e.g., VEGFR-2, C-RAF, B-RAF) for treating tyrosine kinase-related diseases. 

Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof

Growing community of inventors

Beijing, China

Hailong Yang